-
N4-Acetylcytidine: Unraveling RNA Acetylation and Enzyme Spe
2026-05-20
Explore the unique biochemical roles of N4-Acetylcytidine in RNA epigenetics research. This article offers a comprehensive perspective on its structural features, enzyme interactions, and advanced assay design—distinct from existing content.
-
Imipramine as a Tricyclic Antidepressant: Beyond Mood Disord
2026-05-19
Explore Imipramine’s unique role as a tricyclic antidepressant and its expanding utility in glioma cell autophagy research, HL-60 apoptosis assays, and immunomodulatory studies. This article delivers a deep dive into molecular mechanisms and practical assay insights, setting it apart from existing protocols.
-
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO): Technica
2026-05-19
The Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) safeguards protein samples from endogenous protease and phosphatase activity during extraction, especially for mass spectrometry workflows. This product should not be used in protocols targeting metalloproteinases unless EDTA is supplemented, or in non-aqueous extraction scenarios.
-
EPZ-6438: Transforming EZH2 Inhibition in Resistant Cancer M
2026-05-18
Explore how EPZ-6438, a potent EZH2 inhibitor, advances epigenetic cancer research by overcoming resistance mechanisms in aggressive tumor models. This article delivers new assay insights and translational strategies for researchers.
-
EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1
2026-05-18
EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent for peptide synthesis, bioconjugation, and nucleotide coupling workflows. It is designed for controlled amide and ester bond formation in in vitro biochemical protocols, but is not suitable for in vivo or clinical applications due to a lack of supporting data.
-
PreScission Protease (PSP): Technical Guide for Tag Cleavage
2026-05-17
PreScission Protease (PSP) provides precise, low-temperature cleavage of fusion tags from recombinant proteins, supporting native protein recovery in purification workflows. It is specifically suited for protocols requiring high specificity at 4°C and should not be used with substrates lacking the HRV 3C recognition site or for applications outside molecular biology and biochemistry.
-
Redefining mRNA Capping: ARCA’s Role in Next-Gen Translation
2026-05-16
This thought-leadership article explores the mechanistic and translational impact of Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, in enabling robust synthetic mRNA translation. We integrate experimental findings, highlight strategic applications in hiPSC differentiation, and deliver actionable guidance for researchers seeking to maximize mRNA stability and protein expression. The discussion bridges emerging best practices, competitive capping technologies, and future prospects for mRNA therapeutics—advancing beyond conventional product summaries.
-
Dual-Action Kinase Inhibitors Promote p38α MAPK Dephosphoryl
2026-05-15
This study reveals that select kinase inhibitors can simultaneously block the p38α MAP kinase active site and stimulate its dephosphorylation by phosphatases, a dual mechanism not previously characterized. The findings open new avenues for developing more effective and specific kinase inhibitors for cellular signaling and cancer research.
-
Polybrene (Hexadimethrine Bromide): Optimizing Viral Transdu
2026-05-15
Polybrene (Hexadimethrine Bromide) is a validated enhancer for both viral gene delivery and lipid-mediated DNA transfection, enabling robust, reproducible workflows even in challenging cell types. This guide delivers actionable protocols, advanced applications, and troubleshooting strategies to maximize assay success with APExBIO’s 10 mg/mL formulation.
-
Over-Expression and Kinetic Analysis of M. tuberculosis WecA
2026-05-14
This study details the successful over-expression, purification, and kinetic characterization of the membrane protein WecA from Mycobacterium tuberculosis. The methodology enables reliable investigation of WecA's enzymatic properties and lays the groundwork for new anti-tuberculosis drug discovery.
-
Protease Inhibitor Cocktail (EDTA-Free, 200X): Science & Pro
2026-05-14
The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is a broad-spectrum, EDTA-free protein extraction protease inhibitor that prevents protein degradation in workflows sensitive to divalent cations. Its unique formulation is validated for Western blotting, co-immunoprecipitation, and phosphorylation analysis, offering robust serine protease inhibition with high stability (12 months at -20°C).
-
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO): Technica
2026-05-13
The Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) offers targeted protein degradation prevention during cell and tissue extraction, ensuring compatibility with mass spectrometry workflows. It is best applied in proteomic and biochemical sample preparation where broad-spectrum, MS-safe protease inhibition is required, but should be avoided when metalloproteinase inhibition is needed without an added EDTA supplement.
-
CENPI Drives Breast Cancer Progression via Wnt/β-Catenin Mod
2026-05-13
Wu et al. (2025) reveal that centromere protein I (CENPI) is overexpressed in breast cancer and actively promotes tumorigenesis by modulating the Wnt/β-catenin signaling pathway. Their integrative approach demonstrates CENPI's role as a potential oncogenic driver and biomarker, with implications for targeted breast cancer therapy.
-
Metabolic Intervention Sensitizes Tumors to Ferroptosis/Cupr
2026-05-12
This study presents a metabolic intervention strategy that enhances both ferroptosis and cuproptosis in tumor cells by targeting glycolysis and NAD+ metabolism. The approach, using a copper-tannic acid nanoplatform with encapsulated STF-31, results in improved anti-tumor immunity and highlights new directions for regulated cell death-based cancer therapy.
-
Adefovir Dipivoxil: Mechanistic and Clinical Advances in HBV
2026-05-12
Hadziyannis and Papatheodoridis provide a comprehensive review of adefovir dipivoxil’s mechanistic specificity and durable efficacy in chronic hepatitis B virus (HBV) infection. The paper establishes adefovir as a selective, low-resistance nucleotide analog antiviral, supporting its use in both wild-type and resistant HBV cases and setting a benchmark for future HBV antiviral research.